Registered number
05049997
Axis Pharma Ltd
Unaudited Filleted Accounts
31 January 2024
Axis Pharma Ltd
Registered number: 05049997
Balance Sheet
as at 31 January 2024
Notes 2024 2023
£ £
Current assets
Debtors 4 17,049 16,433
Cash at bank and in hand 514,302 478,722
531,351 495,155
Creditors: amounts falling due within one year 5 (69,058) (95,380)
Net current assets 462,293 399,775
Net assets 462,293 399,775
Capital and reserves
Called up share capital 1 1
Profit and loss account 462,292 399,774
Shareholders' funds 462,293 399,775
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
D A Cohen
Director
Approved by the board on 24 October 2024
Axis Pharma Ltd
Notes to the Accounts
for the year ended 31 January 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Freehold buildings over 50 years
Leasehold land and buildings over the lease term
Plant and machinery over 5 years
Fixtures, fittings, tools and equipment over 5 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 February 2023 329
At 31 January 2024 329
Depreciation
At 1 February 2023 329
At 31 January 2024 329
Net book value
At 31 January 2024 -
4 Debtors 2024 2023
£ £
Trade debtors 17,049 16,433
5 Creditors: amounts falling due within one year 2024 2023
£ £
Taxation and social security costs 33,591 30,422
Other creditors 35,467 64,958
69,058 95,380
6 Controlling party
The company is under the control of the directors.
7 Other information
Axis Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
108 Picotts End
Hemel Hempstead
HP1 3AU
Axis Pharma Ltd 05049997 false 2023-02-01 2024-01-31 2024-01-31 VT Final Accounts July 2024 D A Cohen No description of principal activity 05049997 2022-02-01 2023-01-31 05049997 core:WithinOneYear 2023-01-31 05049997 core:ShareCapital 2023-01-31 05049997 core:RetainedEarningsAccumulatedLosses 2023-01-31 05049997 2023-02-01 2024-01-31 05049997 bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 05049997 bus:AuditExemptWithAccountantsReport 2023-02-01 2024-01-31 05049997 bus:Director40 2023-02-01 2024-01-31 05049997 1 2023-02-01 2024-01-31 05049997 2 2023-02-01 2024-01-31 05049997 countries:England 2023-02-01 2024-01-31 05049997 bus:FRS102 2023-02-01 2024-01-31 05049997 bus:FilletedAccounts 2023-02-01 2024-01-31 05049997 2024-01-31 05049997 core:WithinOneYear 2024-01-31 05049997 core:ShareCapital 2024-01-31 05049997 core:RetainedEarningsAccumulatedLosses 2024-01-31 05049997 core:PlantMachinery 2024-01-31 05049997 2023-01-31 05049997 core:PlantMachinery 2023-01-31 iso4217:GBP xbrli:pure